Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Director · PRESIDENT AND CEO | September 03, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date September 03, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2036-09-03 | Direct | 320,000 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 320,000 · Balance 320,000 F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan. F2: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 160,000 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Grant · Acquired 160,000 · Balance 160,000 F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.
F2: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantRestricted Stock Units · Derivative | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001781450-26-000002 · form4-09042026_060904.xml · derivative · entry 2 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 10:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001781450-26-000002 · form4-09042026_060904.xml · derivative · entry 1 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2036-09-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan. F2 · balance_after: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 12:25 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 56,000 | $1.81 | $101,360.00 |
DisclosureSEC source: 0001781450-25-000005 · form4-12232025_121255.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,516 Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-25-023700 · form4-09042025_050901.xml · derivative · entry 3 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2035-09-03 F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F4 · balance_after: Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 195,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023700 · form4-09042025_050901.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,344,418 F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 263,960 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010099 · form4-04032024_050412.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,149,418 F1 · price: Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). F2 · ownership.direct: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 10:50 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 16,129 | $1.41 | $22,741.89 |
DisclosureSEC source: 0001415889-23-014454 · form4-10202023_061001.xml · nonDerivative · entry 2 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,516 Read SEC document |
| October 19, 2023 Filed Oct 20, 2023 10:50 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 48,387 | $1.40 | $67,741.80 |
DisclosureSEC source: 0001415889-23-014454 · form4-10202023_061001.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,387 Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 800,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-093073 · tm2324046-4_4seq1.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,885,458 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. Of such shares, 200,000 shares were fully-vested upon grant and the remaining 600,000 shares vest over a two-year period beginning on the date of grant in eight equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:02 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098949 · tm2225460-6_4seq1.xml · derivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 20:05 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 68,000 | $1.50 | $102,000.00 |
DisclosureSEC source: 0001104659-22-045488 · tm2212654-1_4seq1.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 F1 · ownership.direct: The reporting person holds the shares in an account with his spouse as joint tenants. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 22:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 637,531 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-028157 · tm227910-1_4seq1.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,085,458 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 21:02 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 447,927 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-094753 · tm2027548d2_4.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 447,927 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| August 11, 2020 Filed Aug 14, 2020 21:01 UTC Amendment | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 447,927 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-095623 · tm2027654-1_4a.xml · nonDerivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 447,927 F1 · security: The original Form 4, filed on August 13, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the vesting schedule of the restricted shares. F2 · security: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F2 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). The restricted shares vest in 16 equal quarterly increments over a four-year period, commencing on the date of grant. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan. F3 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:56 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 1,600,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001144204-19-033654 · tv524753_4.xml · derivative · entry 1 Bashan Dror · CIK 0001781450 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600,000 Underlying: Common Stock · 1,600,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.